Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 152 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Botox® Clear all
Terminated Phase 2 Interventional Results available

Dysport in Vulvodynia Phase II Study

NCT03598777
View directory record Official record
Conditions
Vulvodynia
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Miami, Florida • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Not applicable Interventional Results available

Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis

NCT01811004
View directory record Official record
Conditions
Hyperhidrosis
Interventions
miraDry, Nd:YAG Laser, Botox®
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 21, 2026, 5:30 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00439140
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

NCT05308979
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge, Urge Incontinence, Urinary Urgency, Urinary Frequency
Interventions
OnabotulinumtoxinA 100 UNT [Botox]
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Results available

Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine

NCT02037425
View directory record Official record
Conditions
Chronic Migraine
Interventions
onabotulinumtoxinA
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 21, 2026, 5:30 PM EDT
Completed No phase listed Observational Results available

CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy

NCT00836017
View directory record Official record
Conditions
Cervical Dystonia
Interventions
No Intervention
Other
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

NCT02176356
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
Interventions
onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC
Biological · Drug · Device
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 21, 2026, 5:30 PM EDT
Withdrawn Phase 4 Interventional

Prophylactic Analgesia for Bladder Botox Injections

NCT06514430
View directory record Official record
Conditions
Urinary Incontinence, Urinary Incontinence, Urge, Overactive Bladder
Interventions
Phenazopyridine, 1% lidocaine with sodium bicarbonate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 21, 2026, 5:30 PM EDT
Terminated Phase 2 Interventional Results available

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

NCT00711087
View directory record Official record
Conditions
Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Interventions
BOTOX-A, Saline injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 21, 2026, 5:30 PM EDT
Not listed Phase 4 Interventional

BOTOX® at the Time of Prolapse Surgery for OAB

NCT04807920
View directory record Official record
Conditions
Urinary Bladder, Overactive, Pelvic Organ Prolapse
Interventions
OnabotulinumtoxinA 100 UNT, Injectable saline
Drug · Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines

NCT04631588
View directory record Official record
Conditions
Facial Fine Lines
Interventions
Botox, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
Miami, Florida • New York, New York • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 21, 2026, 5:30 PM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines

NCT02718118
View directory record Official record
Conditions
Glabellar Lines, Wrinkles
Interventions
Dysport reconstituted at 1.5 mL (0.05 mL/injection), Dysport reconstituted at 2.5 mL (0.08 mL/injection)
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Greenwood Village, Colorado • Coral Gables, Florida • Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of OnabotulinumtoxinA (BOTOX®) on Stress

NCT06778421
View directory record Official record
Conditions
Stress (Psychology), Stress, Healthy Adult Female Participants, Stress, Psychologic, Stress, Psychological Cumulative, Stress, Physiological, Stress Response, Stress Levels, Stress Perception
Interventions
Intramuscular injection, OnabotulinumtoxinA (Botox®) Injections, Sodium Chloride
Procedure · Drug · Other
Lead sponsor
Center for Advanced Facial Plastic Surgery
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome

NCT02070302
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Benjamin Sucher
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia

NCT00564681
View directory record Official record
Conditions
Cervical Dystonia
Interventions
botulinum toxin type A, botulinum toxin type A Formulation 2, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 21, 2026, 5:30 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer

NCT07796490
View directory record Official record
Conditions
Prostate Cancer
Interventions
OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo
Drug · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Not applicable Interventional Results available

Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness

NCT01129583
View directory record Official record
Conditions
Post Traumatic Stiffness
Interventions
Botulinum Toxin Type A, Saline
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

NCT02498769
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Joseph Mathew, M.D.
Other
Eligibility
50 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)

NCT01502956
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
InterStim® device, Botox® injection
Device · Drug
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • La Jolla, California • Albuquerque, New Mexico + 6 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

BOTOX® for the Treatment of Platysma Prominence

NCT03915067
View directory record Official record
Conditions
Platysma Prominence
Interventions
BOTOX® purified neurotoxin complex, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Los Angeles, California • Coral Gables, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 21, 2026, 5:30 PM EDT
Terminated Phase 3 Interventional Results available

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

NCT02660138
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 21, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

A Research Study for Patients With Overactive Bladder

NCT00168454
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
botulinum toxin Type A, Placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 21, 2026, 5:30 PM EDT